Study reveals vulnerability of common pathogenic viruses
Posted: 13 June 2019 | Victoria Rees (Drug Target Review) | No comments yet
Researchers have developed a stabilisation technique for widespread viruses, creating drug opportunity.


A study completed by researchers at the University of Leuven, Belgium and University of Helsinki has revealed a new feature of a large class of pathogenic viruses. The findings provide opportunities for the development of antiviral medications for the common cold, polio and other illnesses.
Picornaviruses include rhinoviruses and enteroviruses. Rhinoviruses cause cold infections and contribute to asthma. Enteroviruses infect millions a year with meningitis, encephalitis and polio.
When the viruses interact with host cells, their shape evolves. The researchers discovered a compound which stabilised a model virus to prevent it from changing. They performed cryo-electron microscopy (cryo-EM) of the drug-virus complex to determine how the drug exerted its effect.
Biomarkers are redefining how precision therapies are discovered, validated and delivered.
This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.
Inside the report:
- How leading organisations are reshaping strategy with biomarker-led approaches
- Better tools for real-time decision-making – turning complex data into faster insights
- Global standardisation and assay sensitivity – what it takes to scale across networks
Discover how biomarker science is addressing the biggest hurdles in drug discovery, translational research and precision medicine – access your free copy today
The researchers identified a previously unknown pocket on the surface of the virus. The compound had lodged in this indentation, stopping it from changing shape and therefore blocking any interaction with host cells. The team then used the compound as a pathway to generate multiple variants of the antiviral molecule to maximise the activity against a broad range of picornaviruses.
It is possible that the newly discovered pocket may mutate to make picornaviruses resistant to therapies developed against them. However, the authors suggest the pocket may be crucial enough for viral replication and that viruses containing mutant versions may be less viable, making the drug relatively “resistance-proof.”
Further work to develop these compounds into effective drugs is ongoing. “These results open up a new avenue for the design of broad-spectrum antivirals against rhinoviruses and enteroviruses, both of which are major human pathogens,” said Johan Neyts, an author of the study.
The finds were published in PLOS Biology.
Related topics
Disease Research, Drug Discovery, Drug Targets
Related conditions
Asthma, Common cold, encephalitis, Meningitis, Polio
Related organisations
PLOS Biology, University of Helsinki, University of Leuven
Related people
Johan Neyts